Findings show risk cut in half based on electronic health record data
TUESDAY, June 25, 2024 (HealthDay News) — Semaglutide may cut incidence and recurrence of alcohol use disorder (AUD) in patients with obesity, according to a study published online May 28 in Nature Communications.
William Wang, from Case Western Reserve University in Cleveland, and colleagues used electronic health records of 83,825 patients with obesity to examine associations between AUD and semaglutide use.
The researchers found that compared with other antiobesity medications, semaglutide was associated with a 50 to 56 percent lower risk for both the incidence and recurrence of AUD over a 12-month follow-up period. Across gender, age group, race, and in patients with and without type 2 diabetes (T2DM), similar associations were seen. An additional study population of 598,803 patients with T2DM showed similar results.
“In summary, our results find an association between reduced risk for incident and AUD relapse with the prescription of semaglutide in patients with obesity or T2DM,” the authors write. “While these findings provide preliminary evidence of the potential benefit of semaglutide in AUD in real-world populations further randomized clinical trials are needed to support its use clinically for AUD.”
Calorie Restriction and Mediterranean-Style Diet Yield Similar Weight Loss 
Strength Training May Cut GDM Risk in Pregnant Women With Overweight, Obesity 
Most Metabolic and Bariatric Surgery Candidates Meet Criteria for Clinical Obesity 
Central Adiposity Reclassifies Cardiovascular Risk Across BMI Spectrum 
2011 to 2021 Saw Heart Failure-Related Hospitalization Rise in CKD 
Machine Learning Model IDs Heart Failure With Reduced Ejection Fraction Using Routine Lab Indicators 
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths 
High-Dose Omega-3 Linked to A-Fib Risk in Patients With High CVD Risk 
